Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 233

1.

Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy.

Gracheva N, Müller C, Talip Z, Heinitz S, Köster U, Zeevaart JR, Vögele A, Schibli R, van der Meulen NP.

EJNMMI Radiopharm Chem. 2019 Jul 10;4(1):12. doi: 10.1186/s41181-019-0063-6.

2.

Comparison of desferrioxamine and NODAGA for the gallium-68 labeling of exendin-4.

Kaeppeli SAM, Schibli R, Mindt TL, Behe M.

EJNMMI Radiopharm Chem. 2019 May 16;4(1):9. doi: 10.1186/s41181-019-0060-9.

3.

Structure-Affinity Relationships of 2,3,4,5-Tetrahydro-1H-3-benzazepine and 6,7,8,9-Tetrahydro-5H-benzo[7]annulen-7-amine Analogues and the Discovery of a Radiofluorinated 2,3,4,5-Tetrahydro-1H-3-benzazepine Congener for Imaging GluN2B Subunit-Containing N-Methyl-d-aspartate Receptors.

Ahmed H, Haider A, Varisco J, Stanković M, Wallimann R, Gruber S, Iten I, Häne S, Müller Herde A, Keller C, Schibli R, Schepmann D, Mu L, Wünsch B, Ametamey SM.

J Med Chem. 2019 Nov 14;62(21):9450-9470. doi: 10.1021/acs.jmedchem.9b00812. Epub 2019 Oct 28.

PMID:
31657559
4.

Cholecystokinin-2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma - Results of the Lumed Phase 0a Study.

Rottenburger C, Nicolas GP, McDougall L, Kaul F, Cachovan M, Vija AH, Schibli R, Geistlich S, Schumann A, Rau T, Glatz K, Behe M, Christ ER, Wild D.

J Nucl Med. 2019 Sep 13. pii: jnumed.119.233031. doi: 10.2967/jnumed.119.233031. [Epub ahead of print]

PMID:
31519804
5.

Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute.

Müller C, De Prado Leal M, Dominietto MD, Umbricht CA, Safai S, Perrin RL, Egloff M, Bernhardt P, van der Meulen NP, Weber DC, Schibli R, Lomax AJ.

Pharmaceutics. 2019 Sep 2;11(9). pii: E450. doi: 10.3390/pharmaceutics11090450.

6.

Therapeutic Potential of 47Sc in Comparison to 177Lu and 90Y: Preclinical Investigations.

Siwowska K, Guzik P, Domnanich KA, Monné Rodríguez JM, Bernhardt P, Ponsard B, Hasler R, Borgna F, Schibli R, Köster U, van der Meulen NP, Müller C.

Pharmaceutics. 2019 Aug 20;11(8). pii: E424. doi: 10.3390/pharmaceutics11080424.

7.

Synthesis and Structure-Affinity Relationship of Small Molecules for Imaging Human CD80 by Positron Emission Tomography.

Taddio MF, Mu L, Castro Jaramillo CA, Bollmann T, Schmid DM, Muskalla LP, Gruene T, Chiotellis A, Ametamey SM, Schibli R, Krämer SD.

J Med Chem. 2019 Sep 12;62(17):8090-8100. doi: 10.1021/acs.jmedchem.9b00858. Epub 2019 Aug 29.

PMID:
31430137
8.

Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting.

Kaeppeli SAM, Jodal A, Gotthardt M, Schibli R, Béhé M.

Mol Pharm. 2019 Sep 3;16(9):3760-3769. doi: 10.1021/acs.molpharmaceut.9b00271. Epub 2019 Aug 21.

PMID:
31393738
9.

Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer.

Müller C, Singh A, Umbricht CA, Kulkarni HR, Johnston K, Benešová M, Senftleben S, Müller D, Vermeulen C, Schibli R, Köster U, van der Meulen NP, Baum RP.

EJNMMI Res. 2019 Jul 25;9(1):68. doi: 10.1186/s13550-019-0538-1.

10.

High-Resolution SPECT Imaging of Stimuli-Responsive Soft Microrobots.

Iacovacci V, Blanc A, Huang H, Ricotti L, Schibli R, Menciassi A, Behe M, Pané S, Nelson BJ.

Small. 2019 Aug;15(34):e1900709. doi: 10.1002/smll.201900709. Epub 2019 Jul 15.

PMID:
31304653
11.

Radiation dosimetry of [18F]-PSS232-a PET radioligand for imaging mGlu5 receptors in humans.

Sah BR, Sommerauer M, Mu L, Gonzalez GP, Geistlich S, Treyer V, Schibli R, Buck A, Warnock G, Ametamey SM.

EJNMMI Res. 2019 Jun 25;9(1):56. doi: 10.1186/s13550-019-0522-9.

12.

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.

Müller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, Zeevaart JR, Köster U, Schibli R, van der Meulen NP.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1919-1930. doi: 10.1007/s00259-019-04345-0. Epub 2019 May 27.

13.

Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14-16, 2018; Vienna, Austria.

Lim MS, Beyer T, Babayan A, Bergmann M, Brehme M, Buyx A, Czernin J, Egger G, Elenitoba-Johnson KSJ, Gückel B, Jačan A, Haslacher H, Hicks RJ, Kenner L, Langanke M, Mitterhauser M, Pichler BJ, Salih HR, Schibli R, Schulz S, Simecek J, Simon J, Soares MO, Stelzl U, Wadsak W, Zatloukal K, Zeitlinger M, Hacker M.

Mol Imaging Biol. 2019 May 2. doi: 10.1007/s11307-019-01361-2. [Epub ahead of print]

PMID:
31049831
14.

Recent progress in allosteric modulators for GluN2A subunit and development of GluN2A-selective nuclear imaging probes.

He Y, Mu L, Ametamey SM, Schibli R.

J Labelled Comp Radiopharm. 2019 Jun 30;62(8):552-560. doi: 10.1002/jlcr.3744.

PMID:
31037756
15.

Targeted 64 Cu-labeled gold nanoparticles for dual imaging with positron emission tomography and optical imaging.

Pretze M, van der Meulen NP, Wängler C, Schibli R, Wängler B.

J Labelled Comp Radiopharm. 2019 Jun 30;62(8):471-482. doi: 10.1002/jlcr.3736. Epub 2019 May 28.

PMID:
30980411
16.

Implementation of a new separation method to produce qualitatively improved 64 Cu.

van der Meulen NP, Hasler R, Blanc A, Farkas R, Benešová M, Talip Z, Müller C, Schibli R.

J Labelled Comp Radiopharm. 2019 Jun 30;62(8):460-470. doi: 10.1002/jlcr.3730.

PMID:
30916408
17.

First Clinicopathologic Evidence of a Non-PSMA-Related Uptake Mechanism for 68Ga-PSMA-11 in Salivary Glands.

Rupp NJ, Umbricht CA, Pizzuto DA, Lenggenhager D, Töpfer A, Müller J, Muehlematter UJ, Ferraro DA, Messerli M, Morand GB, Huber GF, Eberli D, Schibli R, Müller C, Burger IA.

J Nucl Med. 2019 Sep;60(9):1270-1276. doi: 10.2967/jnumed.118.222307. Epub 2019 Feb 8.

PMID:
30737300
18.

Preclinical Evaluation of Benzazepine-Based PET Radioligands (R)- and (S)-11C-Me-NB1 Reveals Distinct Enantiomeric Binding Patterns and a Tightrope Walk Between GluN2B- and σ1-Receptor-Targeted PET Imaging.

Haider A, Herde AM, Krämer SD, Varisco J, Keller C, Frauenknecht K, Auberson YP, Temme L, Robaa D, Sippl W, Schibli R, Wünsch B, Mu L, Ametamey SM.

J Nucl Med. 2019 Aug;60(8):1167-1173. doi: 10.2967/jnumed.118.221051. Epub 2019 Jan 25.

PMID:
30683765
19.

Elucidating the Structure-Activity Relationship of the Pentaglutamic Acid Sequence of Minigastrin with Cholecystokinin Receptor Subtype 2.

Ritler A, Shoshan MS, Deupi X, Wilhelm P, Schibli R, Wennemers H, Béhé M.

Bioconjug Chem. 2019 Mar 20;30(3):657-666. doi: 10.1021/acs.bioconjchem.8b00849. Epub 2019 Jan 14.

PMID:
30608664
20.

Visualisation of interstitial lung disease by molecular imaging of integrin αvβ3 and somatostatin receptor 2.

Schniering J, Benešová M, Brunner M, Haller S, Cohrs S, Frauenfelder T, Vrugt B, Feghali-Bostwick CA, Schibli R, Distler O, Mueller C, Maurer B.

Ann Rheum Dis. 2019 Feb;78(2):218-227. doi: 10.1136/annrheumdis-2018-214322. Epub 2018 Nov 17. Erratum in: Ann Rheum Dis. 2019 Jun;78(6):e60.

21.

Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for 64Cu-Based PET Imaging.

Umbricht CA, Benešová M, Hasler R, Schibli R, van der Meulen NP, Müller C.

Mol Pharm. 2018 Dec 3;15(12):5556-5564. doi: 10.1021/acs.molpharmaceut.8b00712. Epub 2018 Oct 30.

PMID:
30376344
22.

Metabotropic glutamate receptor subtype 5 is altered in LPS-induced murine neuroinflammation model and in the brains of AD and ALS patients.

Müller Herde A, Schibli R, Weber M, Ametamey SM.

Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):407-420. doi: 10.1007/s00259-018-4179-9. Epub 2018 Oct 5.

PMID:
30291374
23.

In Vivo Labeling of Plasma Proteins for Imaging of Enhanced Vascular Permeability in the Lungs.

Schniering J, Borgna F, Siwowska K, Benešová M, Cohrs S, Hasler R, van der Meulen NP, Maurer B, Schibli R, Müller C.

Mol Pharm. 2018 Nov 5;15(11):4995-5004. doi: 10.1021/acs.molpharmaceut.8b00606. Epub 2018 Sep 28.

PMID:
30265552
24.

Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma.

Lindenblatt D, Terraneo N, Pellegrini G, Cohrs S, Spycher PR, Vukovic D, Béhé M, Schibli R, Grünberg J.

BMC Cancer. 2018 Sep 25;18(1):922. doi: 10.1186/s12885-018-4836-1.

25.

Ketamine and Ceftriaxone-Induced Alterations in Glutamate Levels Do Not Impact the Specific Binding of Metabotropic Glutamate Receptor Subtype 5 Radioligand [18F]PSS232 in the Rat Brain.

Müller Herde A, Boss SD, He Y, Schibli R, Mu L, Ametamey SM.

Pharmaceuticals (Basel). 2018 Aug 29;11(3). pii: E83. doi: 10.3390/ph11030083.

26.

Evaluation of 99mTc-rhAnnexin V-128 SPECT/CT as a diagnostic tool for early stages of interstitial lung disease associated with systemic sclerosis.

Schniering J, Guo L, Brunner M, Schibli R, Ye S, Distler O, Béhé M, Maurer B.

Arthritis Res Ther. 2018 Aug 16;20(1):183. doi: 10.1186/s13075-018-1681-1.

27.

Diastereomerically Pure 6R- and 6S-3'-Aza-2'-18F-Fluoro-5-Methyltetrahydrofolates Show Unprecedentedly High Uptake in Folate Receptor-Positive KB Tumors.

Boss SD, Müller C, Siwowska K, Schmid RM, Groehn V, Schibli R, Ametamey SM.

J Nucl Med. 2019 Jan;60(1):135-141. doi: 10.2967/jnumed.118.213314. Epub 2018 Jul 24.

PMID:
30042162
28.

Identification and Preclinical Evaluation of a Radiofluorinated Benzazepine Derivative for Imaging the GluN2B Subunit of the Ionotropic NMDA Receptor.

Haider A, Iten I, Ahmed H, Müller Herder A, Gruber S, Krämer SD, Keller C, Schibli R, Wünsch B, Mu L, Ametamey SM.

J Nucl Med. 2018 Jul 20. pii: jnumed.118.212134. doi: 10.2967/jnumed.118.212134. [Epub ahead of print]

29.

Unexpected reactivity of cyclic perfluorinated iodanes with electrophiles.

Gruber S, Ametamey SM, Schibli R.

Chem Commun (Camb). 2018 Aug 9;54(65):8999-9002. doi: 10.1039/c8cc04558e.

PMID:
30027951
30.

Physiologically Based Pharmacokinetic Modelling with Dynamic PET Data to Study the In Vivo Effects of Transporter Inhibition on Hepatobiliary Clearance in Mice.

Taddio MF, Mu L, Keller C, Schibli R, Krämer SD.

Contrast Media Mol Imaging. 2018 Jun 3;2018:5849047. doi: 10.1155/2018/5849047. eCollection 2018.

31.

Combining Albumin-Binding Properties and Interaction with Pemetrexed to Improve the Tissue Distribution of Radiofolates.

Müller C, Guzik P, Siwowska K, Cohrs S, Schmid RM, Schibli R.

Molecules. 2018 Jun 16;23(6). pii: E1465. doi: 10.3390/molecules23061465.

32.

Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.

Umbricht CA, Benešová M, Schibli R, Müller C.

Mol Pharm. 2018 Jun 4;15(6):2297-2306. doi: 10.1021/acs.molpharmaceut.8b00152. Epub 2018 May 2.

PMID:
29684274
33.

Injected Human Muscle Precursor Cells Overexpressing PGC-1α Enhance Functional Muscle Regeneration after Trauma.

Haralampieva D, Salemi S, Betzel T, Dinulovic I, Krämer SD, Schibli R, Sulser T, Handschin C, Ametamey SM, Eberli D.

Stem Cells Int. 2018 Jan 21;2018:4658503. doi: 10.1155/2018/4658503. eCollection 2018.

34.

Radiosynthesis and evaluation of an 18F-labeled silicon containing exendin-4 peptide as a PET probe for imaging insulinoma.

Dialer LO, Jodal A, Schibli R, Ametamey SM, Béhé M.

EJNMMI Radiopharm Chem. 2018;3(1):1. doi: 10.1186/s41181-017-0036-6. Epub 2018 Jan 2.

35.

Improved Syntheses of the Mglu₅ Antagonists MMPEP and MTEP Using Sonogashira Cross-Coupling.

Mu B, Mu L, Schibli R, Ametamey SM, Milicevic Sephton S.

Pharmaceuticals (Basel). 2018 Feb 20;11(1). pii: E24. doi: 10.3390/ph11010024.

36.

Reduced 18F-Folate Conjugates as a New Class of PET Tracers for Folate Receptor Imaging.

Boss SD, Müller C, Siwowska K, Büchel JI, Schmid RM, Groehn V, Schibli R, Ametamey SM.

Bioconjug Chem. 2018 Apr 18;29(4):1119-1130. doi: 10.1021/acs.bioconjchem.7b00775. Epub 2018 Feb 19.

PMID:
29412638
37.

Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.

Benešová M, Umbricht CA, Schibli R, Müller C.

Mol Pharm. 2018 Mar 5;15(3):934-946. doi: 10.1021/acs.molpharmaceut.7b00877. Epub 2018 Feb 5.

PMID:
29400475
38.

Evaluation of 4-oxo-quinoline-based CB2 PET radioligands in R6/2 chorea huntington mouse model and human ALS spinal cord tissue.

Haider A, Spinelli F, Herde AM, Mu B, Keller C, Margelisch M, Weber M, Schibli R, Mu L, Ametamey SM.

Eur J Med Chem. 2018 Feb 10;145:746-759. doi: 10.1016/j.ejmech.2017.12.097. Epub 2018 Jan 5.

PMID:
29353725
39.

Evaluation of 11C-Me-NB1 as a Potential PET Radioligand for Measuring GluN2B-Containing NMDA Receptors, Drug Occupancy, and Receptor Cross Talk.

Krämer SD, Betzel T, Mu L, Haider A, Herde AM, Boninsegni AK, Keller C, Szermerski M, Schibli R, Wünsch B, Ametamey SM.

J Nucl Med. 2018 Apr;59(4):698-703. doi: 10.2967/jnumed.117.200451. Epub 2017 Nov 30.

40.

A first-in-man PET study of [18F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5.

Warnock G, Sommerauer M, Mu L, Pla Gonzalez G, Geistlich S, Treyer V, Schibli R, Buck A, Krämer SD, Ametamey SM.

Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):1041-1051. doi: 10.1007/s00259-017-3879-x. Epub 2017 Nov 27.

PMID:
29177707
41.

Novel peptide probes to assess the tensional state of fibronectin fibers in cancer.

Arnoldini S, Moscaroli A, Chabria M, Hilbert M, Hertig S, Schibli R, Béhé M, Vogel V.

Nat Commun. 2017 Nov 27;8(1):1793. doi: 10.1038/s41467-017-01846-0.

42.

Towards Translational ImmunoPET/MR Imaging of Invasive Pulmonary Aspergillosis: The Humanised Monoclonal Antibody JF5 Detects Aspergillus Lung Infections In Vivo.

Davies G, Rolle AM, Maurer A, Spycher PR, Schillinger C, Solouk-Saran D, Hasenberg M, Weski J, Fonslet J, Dubois A, Boschetti F, Denat F, Gunzer M, Eichner M, Ryder LS, Jensen M, Schibli R, Pichler BJ, Wiehr S, Thornton CR.

Theranostics. 2017 Aug 11;7(14):3398-3414. doi: 10.7150/thno.20919. eCollection 2017.

43.

Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals.

Müller C, Farkas R, Borgna F, Schmid RM, Benešová M, Schibli R.

Bioconjug Chem. 2017 Sep 20;28(9):2372-2383. doi: 10.1021/acs.bioconjchem.7b00378. Epub 2017 Sep 12.

PMID:
28898054
44.

Therapeutic Radiometals Beyond 177Lu and 90Y: Production and Application of Promising α-Particle, β--Particle, and Auger Electron Emitters.

Müller C, van der Meulen NP, Benešová M, Schibli R.

J Nucl Med. 2017 Sep;58(Suppl 2):91S-96S. doi: 10.2967/jnumed.116.186825. Review.

45.

Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with 152Tb-DOTATOC.

Baum RP, Singh A, Benešová M, Vermeulen C, Gnesin S, Köster U, Johnston K, Müller D, Senftleben S, Kulkarni HR, Türler A, Schibli R, Prior JO, van der Meulen NP, Müller C.

Dalton Trans. 2017 Oct 31;46(42):14638-14646. doi: 10.1039/c7dt01936j.

PMID:
28825750
46.

Folate Receptor-Positive Gynecological Cancer Cells: In Vitro and In Vivo Characterization.

Siwowska K, Schmid RM, Cohrs S, Schibli R, Müller C.

Pharmaceuticals (Basel). 2017 Aug 15;10(3). pii: E72. doi: 10.3390/ph10030072.

47.

Dual, Site-Specific Modification of Antibodies by Using Solid-Phase Immobilized Microbial Transglutaminase.

Spycher PR, Amann CA, Wehrmüller JE, Hurwitz DR, Kreis O, Messmer D, Ritler A, Küchler A, Blanc A, Béhé M, Walde P, Schibli R.

Chembiochem. 2017 Oct 5;18(19):1923-1927. doi: 10.1002/cbic.201700188. Epub 2017 Aug 29.

PMID:
28771896
48.

A Short-Term Biological Indicator for Long-Term Kidney Damage after Radionuclide Therapy in Mice.

Pellegrini G, Siwowska K, Haller S, Antoine DJ, Schibli R, Kipar A, Müller C.

Pharmaceuticals (Basel). 2017 Jun 21;10(2). pii: E57. doi: 10.3390/ph10020057.

49.

First-in-Human PET/CT Imaging of Metastatic Neuroendocrine Neoplasms with Cyclotron-Produced 44Sc-DOTATOC: A Proof-of-Concept Study.

Singh A, van der Meulen NP, Müller C, Klette I, Kulkarni HR, Türler A, Schibli R, Baum RP.

Cancer Biother Radiopharm. 2017 May;32(4):124-132. doi: 10.1089/cbr.2016.2173.

PMID:
28514206
50.

Radiolabeled 111In-FGF-2 Is Suitable for In Vitro/Ex Vivo Evaluations and In Vivo Imaging.

Moscaroli A, Jones G, Lühmann T, Meinel L, Wälti S, Blanc A, Fischer E, Hilbert M, Schibli R, Béhé M.

Mol Pharm. 2017 Mar 6;14(3):639-648. doi: 10.1021/acs.molpharmaceut.6b00913. Epub 2017 Feb 21.

PMID:
28221043

Supplemental Content

Loading ...
Support Center